Fruits Bio and Merck Announce R&D Collaboration in Autoimmune Illness Analysis –
What it is best to know:
- Fruits Bio, a knowledge and expertise firm that mixes medical and biospecimen information, introduced an R&D collaboration with Merck, often known as MSD, exterior the US and Canada, initially within the discipline of autoimmune illnesses.
- Beneath the phrases of the framework settlement, Merck may have entry to each medical (digital well being data, laboratories, medication) and paired biospecimen information (tissue and blood) from totally different cohorts of various sizes and {qualifications}. This project-based collaboration leverages Fruits's distinctive capacity to construct each retrospective and potential anonymized multimodal datasets in a disease-defined method.
Advancing pharmaceutical analysis via complete affected person information and strategic partnerships
Fruits Bio, a spin-off of Intermountain Well being, owns unique rights to an intensive assortment of anonymized digital well being data and biospecimen information spanning greater than 40 years. With a constantly rising repository of greater than 5 million samples, the platform considerably accelerates affected person recruitment for pharmaceutical analysis, serving to corporations with speedy analysis queries.
Collaboration with Intermountain Well being facilitates speedy recruitment of potential medical trial contributors. Moreover, the platform permits researchers to carry out speedy searches throughout totally different information varieties, supporting cutting-edge analysis from population-wide genetic research to drug discovery. In November 2023, Fruits Bio secured investments from the Merck International Well being Innovation Fund and Amgen Ventures, permitting additional growth of the database and growth in collaboration with pharmaceutical companions.
“Our collaboration with Merck represents an vital milestone in our mission to speed up healthcare analysis,” mentioned Lincoln Nadauld, MD, Ph.D., president and CEO of Fruits Bio. “This settlement illustrates the necessity for speedy entry to high-quality longitudinal affected person information spanning many years to tell medical analysis.”